We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Zimmer Biomet Holdings Inc | NYSE:ZBH | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.51 | 0.47% | 108.22 | 110.1925 | 108.19 | 108.77 | 1,164,629 | 01:00:00 |
As filed with the Securities and Exchange Commission on June 5, 2024
Registration No. 333-______
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
ZIMMER BIOMET HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 13-4151777 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
345 East Main Street
Warsaw, Indiana 46580
(Address of Principal Executive Offices) (Zip Code)
ZIMMER BIOMET HOLDINGS, INC. EMPLOYEE STOCK PURCHASE PLAN
(Full title of the plan)
Chad F. Phipps
Senior Vice President, General Counsel and Secretary
Zimmer Biomet Holdings, Inc.
345 East Main Street
Warsaw, Indiana 46580
(Name and address of agent for service)
(574) 373-3333
(Telephone number, including area code, of agent for service)
Copy to:
Christine G. Long
Jason Deppen
Faegre Drinker Biddle & Reath LLP
600 East 96th Street, Suite 600
Indianapolis, Indiana 46240
(317) 569-9600
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
STATEMENT PURSUANT TO GENERAL INSTRUCTION E
OF FORM S-8 REGISTRATION OF ADDITIONAL SECURITIES
Zimmer Biomet Holdings, Inc. (the Registrant) filed a Registration Statement on Form S-8 (File No. 333-101243) with the Securities and Exchange Commission (the Commission) on November 15, 2002 (the Initial Registration Statement), which registered shares of the Registrants Common Stock, par value $0.01 per share (the Common Stock), available for issuance under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan (the ESPP). Pursuant to General Instruction E to Form S-8, the contents of the Initial Registration Statement are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein.
The Registrant has filed this Form S-8 Registration Statement (this Registration Statement) to register 10,000,000 additional shares of Common Stock under the ESPP, which shares represent an increase in the number of shares available for issuance under the ESPP that was approved by the Registrants stockholders on May 10, 2024 (the Additional Shares).
This Registration Statement is hereby filed to reflect that, following the date hereof, the Additional Shares may be issued and are registered under the ESPP.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The following documents of the Registrant filed with the Commission are incorporated by reference into this Registration Statement:
| the Registrants Annual Report on Form 10-K for the fiscal year ended December 31, 2023; |
| the information specifically incorporated by reference into the Registrants Annual Report on Form 10-K for the fiscal year ended December 31, 2023 from its Definitive Proxy Statement on Schedule 14A filed with the Commission on March 27, 2024; |
| the Registrants Quarterly Report on Form 10-Q for the quarter ended March 31, 2024; |
| the Registrants Current Reports on Form 8-K filed on January 5, 2024 and May 15, 2024; and |
| the description of the Registrants Common Stock contained in the Registrants Registration Statement on Form 10-12B, filed on March 26, 2001, as updated by the description of the Registrants Common Stock contained in Exhibit 4.1 to the Registrants Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on February 23, 2024 , including any amendment or report filed for the purpose of updating such description. |
All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), (other than Current Reports furnished under Items 2.02 or 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicate that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.
Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4. Description of Securities
Not applicable.
Item 5. Interests of Named Experts and Counsel
Not applicable.
Item 6. Indemnification of Directors and Officers
Section 145 of the Delaware General Corporation Law (the DGCL) provides that a corporation may indemnify any current or former director, officer, employee or agent against expenses (including attorneys fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with civil, criminal, administrative or investigative actions, suits or proceedings, other than a derivative action by or in the right of the corporation, if the director, officer, employee or agent acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if he or she had no reasonable cause to believe his or her conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses incurred in connection with the defense or settlement of such actions, and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by any by-law, agreement, vote of stockholders or disinterested directors or otherwise.
The Registrants Restated Certificate of Incorporation provides that each person who was or is made a party or is threatened to be made a party to or is involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person, or a person of whom such person is the legal representative, is or was a director or officer of the Registrant or, while a director or officer of the Registrant, is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, will be indemnified and held harmless by the Registrant to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended to provide broader indemnification rights than authorized prior to such amendment. The Registrant will indemnify such persons against the expenses, liabilities and loss, including attorneys fees, judgments, fines and amounts paid in settlement, reasonably incurred by the person in connection with the action, suit or proceeding if the following standards are met:
| the person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the Registrants best interests, and |
| with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. |
Section 145 of the DGCL also permits a corporation to pay expenses of defense incurred by a director or officer in defending any civil, criminal, administrative or investigative action, suit or proceeding in advance of the final disposition of such action, suit or proceeding upon receipt (in the case of a current director or officer) of an undertaking to repay all amounts advanced if it is ultimately determined that such director or officer is not entitled to be indemnified by the corporation. The Restated Certificate of Incorporation contains such a provision.
Such rights are not exclusive of any other right which any person may have or thereafter acquire under any statute, any provision of the Restated Certificate of Incorporation or the Registrants Restated Bylaws, or any agreement, vote of stockholders or disinterested directors or otherwise. The Registrants Restated Certificate of Incorporation also specifically authorizes the Registrant to maintain insurance and to grant similar indemnification rights to its employees or agents.
The Registrant has provided, consistent with the DGCL, in its Restated Certificate of Incorporation that a director of the Registrant shall not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:
| any breach of the directors duty of loyalty to the Registrant or its stockholders; |
| acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; |
| any transactions from which the director derived an improper personal benefit; or |
| any matter in respect of which the director would be liable under Section 174 of the DGCL. |
Neither the amendment nor repeal of such provision will eliminate or reduce the effect of such provision in respect of any matter occurring, or any cause of action, suit or claim that, but for such provision, would accrue or arise prior to such amendment or repeal.
The Registrant has entered into indemnification agreements with its directors and executive officers providing for mandatory indemnification and advancement of expenses to the fullest extent permitted by applicable law.
In addition, the Registrant has a directors and officers liability policy that insures against certain liabilities, including liabilities under the Securities Act, subject to applicable retentions.
Item 7. Exemption From Registration Claimed
Not applicable.
Item 8. Exhibits
See Exhibit Index preceding the signature page hereto, which is incorporated herein by reference.
Item 9. Undertakings
(A) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act.
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Filing Fee Tables or Calculation of Registration Fee table, as applicable, in the effective Registration Statement.
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(B) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrants annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plans annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(C) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
EXHIBIT INDEX
* | Filed herewith |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Warsaw, State of Indiana, on June 5, 2024.
ZIMMER BIOMET HOLDINGS, INC.
| ||
By: | /s/ Ivan Tornos | |
Ivan Tornos | ||
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their respective capacities and on the respective dates indicated opposite their names. Each person whose signature appears below hereby authorizes each of Ivan Tornos, Suketu Upadhyay and Chad Phipps, each with full power of substitution, to execute in the name and on behalf of such person any amendment (including any post-effective amendment) to this Registration Statement and to file the same, with exhibits thereto, and other documents in connection therewith, making such changes in this Registration Statement as the Registrant deems appropriate, and appoints each of Ivan Tornos, Suketu Upadhyay and Chad Phipps, each with full power of substitution, attorney-in-fact to sign any amendment (including any post-effective amendment) to this Registration Statement and to file the same, with exhibits thereto, and other documents in connection therewith.
Signature |
Title |
Date | ||
/s/ Ivan Tornos Ivan Tornos |
President, Chief Executive Officer and Director (Principal Executive Officer) | June 5, 2024 | ||
/s/ Suketu Upadhyay Suketu Upadhyay |
Chief Financial Officer and Executive Vice President Finance, Operations and Supply Chain (Principal Financial Officer) | June 5, 2024 | ||
/s/ Paul Stellato Paul Stellato |
Vice President, Controller and Chief Accounting Officer (Principal Accounting Officer) | June 5, 2024 | ||
/s/ Christopher Begley Christopher Begley |
Director | June 5, 2024 | ||
/s/ Betsy Bernard Betsy Bernard |
Director | June 5, 2024 | ||
/s/ Michael Farrell Michael Farrell |
Director | June 5, 2024 | ||
/s/ Robert Hagemann Robert Hagemann |
Director | June 5, 2024 | ||
/s/ Arthur Higgins Arthur Higgins |
Director | June 5, 2024 | ||
/s/ Maria Teresa Hilado Maria Teresa Hilado |
Director | June 5, 2024 | ||
/s/ Syed Jafry Syed Jafry |
Director | June 5, 2024 | ||
/s/ Sreelakshmi Kolli Sreelakshmi Kolli |
Director | June 5, 2024 | ||
/s/ Louis A. Shapiro Louis A. Shapiro |
Director | June 5, 2024 |
Exhibit 5.1
Faegre Drinker Biddle & Reath LLP 600 East 96th Street q Suite 600 Indianapolis q Indiana 46240-3789 Phone +1 317 569 9600 Fax +1 317 569 4800 |
June 5, 2024
Zimmer Biomet Holdings, Inc.
345 East Main Street
Warsaw, Indiana 46580
Re: Zimmer Biomet Holdings, Inc. Registration Statement on Form S-8
Ladies and Gentlemen:
We have acted as counsel to Zimmer Biomet Holdings, Inc., a Delaware corporation (the Company), in connection with the preparation and filing with the Securities and Exchange Commission (the Commission) of the Companys Registration Statement on Form S-8 (the Registration Statement) under the Securities Act of 1933, as amended (the Act), registering the offer and sale of up to 10,000,000 additional shares of the Companys common stock, par value $0.01 per share (the Shares), pursuant to the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan (the ESPP).
For purposes of this opinion letter, we have examined the ESPP, the Registration Statement, the Companys Restated Certificate of Incorporation, as currently in effect, the Companys Restated Bylaws, as currently in effect, and the resolutions of the Companys Board of Directors authorizing the issuance of the Shares. We also have examined a certificate of the Secretary of the Company dated the date hereof (the Certificate) and originals, or copies certified or otherwise authenticated to our satisfaction, of such corporate and other records, agreements, instruments, certificates of public officials and documents as we have deemed necessary as a basis for the opinions hereinafter expressed and have made such examination of law as we have deemed relevant and necessary in connection with the opinions hereinafter expressed. As to facts material to this opinion letter, we have relied upon certificates, statements or representations of public officials, of officers and representatives of the Company (including the Certificate) and of others, without any independent verification thereof.
In our examination, we have assumed: (i) the legal capacity of all natural persons; (ii) the genuineness of all signatures, including electronic signatures; (iii) the authenticity of all documents submitted to us as originals; (iv) the conformity to original documents of all documents submitted to us as certified, conformed, photostatic or facsimile copies; (v) the authenticity of the originals of such latter documents; (vi) the truth, accuracy and completeness of the information, representations and warranties contained in the agreements, documents, instruments, certificates and records we have reviewed; and (vii) the absence of any undisclosed modifications to the agreements and instruments reviewed by us.
Based upon such examination and review, and subject to the foregoing and the other qualifications, assumptions and limitations set forth herein, we are of the opinion that all necessary corporate action on the part of the Company has been taken to authorize the issuance and sale of the Shares to be issued in accordance with the ESPP and that, when (a) the Shares have been issued and sold as contemplated in the Registration Statement and related prospectus and in accordance with the ESPP, and (b) the consideration for the Shares specified in the ESPP has been received by the Company, the Shares will be validly issued, fully paid and nonassessable.
We do not express any opinion herein with respect to the laws of any jurisdiction other than, subject to the limitations and assumptions contained herein, the General Corporation Law of the State of Delaware.
This opinion speaks only as of the date the Registration Statement becomes effective under the Act, and we assume no obligation to revise or supplement this opinion thereafter. This opinion is limited to the specific issues addressed herein, and no opinion may be inferred or implied beyond that expressly stated herein.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.
Yours very truly, |
/s/ Faegre Drinker Biddle & Reath LLP |
FAEGRE DRINKER BIDDLE & REATH LLP |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Zimmer Biomet Holdings, Inc. of our report dated February 23, 2024 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in Zimmer Biomet Holdings, Inc.s Annual Report on Form 10-K for the year ended December 31, 2023.
/s/ PricewaterhouseCoopers LLP
Chicago, Illinois
June 5, 2024
Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Zimmer Biomet Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Unit(2) |
Maximum Aggregate Price(2) |
Fee Rate |
Amount of Fee(2) | |||||||
Equity | Common Stock, $0.01 par value per share, to be issued pursuant to the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan | Rule 457(c) and Rule 457(h) |
10,000,000 | $114.47 | $1,144,700,000 | 0.0001476 | $168,957.72 | |||||||
Total Offering Amounts | $1,144,700,000 | $168,957.72 | ||||||||||||
Total Fee Offsets | | |||||||||||||
Net Fee Due | $168,957.72 |
(1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the Employee Stock Purchase Plan by reason of any stock split, stock dividend or other similar transaction effected without the receipt of consideration which results in an increase in the number of shares of outstanding Common Stock. |
(2) | Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and Rule 457(h) of the Securities Act. The proposed maximum offering price per share is calculated on the basis of $114.47, the average of the high and low price of the Registrants Common Stock on May 31, 2024, as reported on the New York Stock Exchange, which is within five business days prior to filing this Registration Statement. |
1 Year Zimmer Biomet Chart |
1 Month Zimmer Biomet Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions